Epsilon Aminocaproic Acid (EACA) for the Reduction of Blood Loss in Total Hip Arthroplasty (THA)

Completed · Not applicable · Has a placebo group

Conditions studied: Degenerative Joint Disease, Osteoarthritis

In brief

You are being asked to take part in this research study because you are scheduled to have total hip replacement (arthroplasty) surgery. The goal of this study is to evaluate the effectiveness of the drug, epsilon Aminocaproic Acid (EACA), in decreasing the need for patients to receive blood after surgery. Currently, EACA is approved by the Federal Drug Administration (FDA) to treat a patient who is bleeding. The investigators plan to use EACA to prevent bleeding during and after surgery; use of this drug as a means of preventing bleeding is not currently approved by the FDA.

Key facts

Study ID

NCT01391182

Run by

Mayo Clinic

People needed

60

Starts

2011-07-01

Expected to finish

2015-01-01

Last updated by the study team

2015-02-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Scheduled for a primary total hip arthroplasty to be performed at the Mayo Clinic
• A preoperative hemoglobin between 10.0 and 13.5

You may not qualify if…

• A preoperative hemoglobin less than 10.0 or greater than 13.5
• Revision arthroplasty;
• Arthroplasty performed for acute fracture
• Inability to obtain informed consent;
• Allergy to EACA
• Pregnancy
• History of coronary stenting < 6 months
• Heart valve replacement;
• Renal disease,
• Coagulopathy, DIC,
• embolic stroke

Where it is running

• Mayo Clinic Jacksonville — Jacksonville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.